Try our Advanced Search for more refined results

Mylan Fights To Invalidate Novartis Blood Transfusion IP

By Bonnie Eslinger (August 4, 2020, 7:43 PM BST) -- Mylan SAS fought back allegations that its planned generic version of a blood transfusion drug made by Novartis AG would infringe Novartis' exclusive rights, arguing that the pharmaceutical giant wasn't entitled to another extension after its protection under Europe's orphan drug program lapsed....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!